Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18024551 | 1.00 | KMT2A (0.39) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL17981244 | 0.87 | PIKFYVE (0.39) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL18024235 | 0.87 | PIKFYVE (0.39) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL17981280 | 0.85 | LDHA (0.39) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL18024671 | 0.84 | PIKFYVE (0.46) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL17980924 | 0.84 | PIKFYVE (0.46) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL18024342 | 0.83 | PRKCZ (0.50) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL18024308 | 0.83 | PRKCZ (0.50) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL17981335 | 0.83 | PRKCZ (0.50) | KMT2APIKFYVECHRNB1CHRNB2CHRNB4 | |
| SCHEMBL18024210 | 0.82 | IMPDH2 (0.38) | KMT2APIKFYVEMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARM INT AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2018-01-04 | — | — | US | disclosed |
| EP-3256217-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016128465-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | KMT2A 2508/4885PIKFYVE 3587/4885CHRNB1 303/4885 |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | KMT2A 2476/4885PIKFYVE 3584/4885CHRNB1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.